알터리 테라퓨틱스(ATHE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.88 (+3.47%), 시가총액 $0.08B, 52주 최저~최고 $2.92 ~ $6.55.
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compo
알터리 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
알터리 테라퓨틱스의 현재 주가는 $3.88 (+3.47%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
알터리 테라퓨틱스의 시가총액은 약 $0.08B입니다.
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lea